BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 32120013)

  • 1. CD27 antigen negative expression indicates poor prognosis in newly diagnosed multiple myeloma.
    Chu B; Bao L; Wang Y; Lu M; Shi L; Gao S; Fang L; Xiang Q; Liu X
    Clin Immunol; 2020 Apr; 213():108363. PubMed ID: 32120013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone marrow B lymphocytes in multiple myeloma and MGUS: Focus on distribution of naïve cells and memory subsets.
    Pojero F; Casuccio A; Giambanco C; Bulati M; Buffa S; Di Bassiano F; Gervasi F; Caruso C; Colonna Romano G
    Leuk Res; 2016 Oct; 49():51-9. PubMed ID: 27552680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high-risk disease.
    Guikema JE; Hovenga S; Vellenga E; Conradie JJ; Abdulahad WH; Bekkema R; Smit JW; Zhan F; Shaughnessy J; Bos NA
    Br J Haematol; 2003 Apr; 121(1):36-43. PubMed ID: 12670329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD44 and CD27 expression pattern in B cell precursor acute lymphoblastic leukemia and its clinical significance.
    Kamazani FM; Bahoush GR; Aghaeipour M; Vaeli S; Amirghofran Z
    Med Oncol; 2013 Mar; 30(1):359. PubMed ID: 23263849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunophenotypic characterization and quantification of neoplastic bone marrow plasma cells by multiparametric flow cytometry and its clinical significance in Korean myeloma patients.
    Cho YU; Park CJ; Park SJ; Chi HS; Jang S; Park SH; Seo EJ; Yoon DH; Lee JH; Suh C
    J Korean Med Sci; 2013 Apr; 28(4):542-9. PubMed ID: 23580331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of cystatin C in multiple myeloma.
    Zhang J; Jiang Y; Guo D; Liu HY; Hong L; Qi J; Huang H
    Int J Lab Hematol; 2022 Feb; 44(1):135-141. PubMed ID: 34549533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A possible role for the loss of CD27-CD70 interaction in myelomagenesis.
    Katayama Y; Sakai A; Oue N; Asaoku H; Otsuki T; Shiomomura T; Masuda R; Hino N; Takimoto Y; Imanaka F; Yasui W; Kimura A
    Br J Haematol; 2003 Jan; 120(2):223-34. PubMed ID: 12542479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating plasma cells in newly diagnosed symptomatic multiple myeloma as a possible prognostic marker for patients with standard-risk cytogenetics.
    Vagnoni D; Travaglini F; Pezzoni V; Ruggieri M; Bigazzi C; Dalsass A; Mestichelli F; Troiani E; Falcioni S; Mazzotta S; Natale A; Angelini M; Ferretti S; Angelini S; Galieni P
    Br J Haematol; 2015 Aug; 170(4):523-31. PubMed ID: 26010293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Achieving minimal residual disease-negative by multiparameter flow cytometry may ameliorate a poor prognosis in MM patients with high-risk cytogenetics: a retrospective single-center analysis.
    Li H; Li F; Zhou X; Mei J; Song P; An Z; Zhao Q; Guo X; Wang X; Zhai Y
    Ann Hematol; 2019 May; 98(5):1185-1195. PubMed ID: 30721336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Diagnostic Value of CD27 Antigen in Patients with Multiple Myeloma].
    Wang H; Liu L; Liu F; Chen LJ; Qu XY; Li JY; Wu YJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Aug; 25(4):1069-1073. PubMed ID: 28823270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
    Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
    Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients.
    Moulopoulos LA; Dimopoulos MA; Kastritis E; Christoulas D; Gkotzamanidou M; Roussou M; Koureas A; Migkou M; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Gika D; Koutoulidis V; Terpos E
    Am J Hematol; 2012 Sep; 87(9):861-4. PubMed ID: 22641455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic Significance of CD27 and CD56 on Newly Diagnosed MM Patients Treated with Bortezomib].
    Zhang CX; Wang HT; Zhang GJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Jun; 29(3):827-831. PubMed ID: 34105479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.
    Li F; Xu Y; Deng P; Yang Y; Sui W; Jin F; Hao M; Li Z; Zang M; Zhou D; Gu Z; Ru K; Wang J; Cheng T; Qiu L
    Oncotarget; 2015 Apr; 6(11):9434-44. PubMed ID: 25831238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma cell maturity as a predictor of prognosis in multiple myeloma.
    Iriyama N; Miura K; Hatta Y; Uchino Y; Kurita D; Takahashi H; Sakagami H; Sakagami M; Kobayashi Y; Nakagawa M; Ohtake S; Iizuka Y; Takei M
    Med Oncol; 2016 Aug; 33(8):87. PubMed ID: 27383407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients.
    Ghermezi M; Li M; Vardanyan S; Harutyunyan NM; Gottlieb J; Berenson A; Spektor TM; Andreu-Vieyra C; Petraki S; Sanchez E; Udd K; Wang CS; Swift RA; Chen H; Berenson JR
    Haematologica; 2017 Apr; 102(4):785-795. PubMed ID: 28034989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [BAFF level in bone marrow and expression of BAFF receptor on B cells in multiple myeloma patients].
    Zhou ZH; Zhang L; Pan QY; Huang BH; Zheng D; Liu JR; Li J; Luo SK
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1131-4. PubMed ID: 23114133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural history of multiple myeloma with de novo del(17p).
    Lakshman A; Painuly U; Rajkumar SV; Ketterling RP; Kapoor P; Greipp PT; Gertz MA; Buadi FK; Lacy MQ; Dingli D; Dispenzieri A; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Leung N; Go RS; Lin Y; Kourelis TV; Warsame R; Lust JA; Russell SJ; Zeldenrust SR; Kyle RA; Kumar SK
    Blood Cancer J; 2019 Mar; 9(3):32. PubMed ID: 30846679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High Expression of Phosphorylated Extracellular Signal-Regulated Kinase (ERK1/2) is Associated with Poor Prognosis in Newly Diagnosed Patients with Multiple Myeloma.
    Fan L; Hong J; Huang H; Fu D; Wu S; Wang Q; Ye Y; Liu Y
    Med Sci Monit; 2017 May; 23():2636-2643. PubMed ID: 28557972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients].
    Deng SH; Xu Y; Mai YJ; Wang YF; Zhao YZ; Zou DH; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):217-21. PubMed ID: 18843972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.